Navigation Links
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Date:6/21/2010

month observed survival advantage for the OGX-011/ TV-1011 arm.

OGX-011/ TV-1011 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and this SATURN trial is being conducted through the Special Protocol Assessment (SPA) process. Earlier this year, the European Medicines Agency indicated that the Committee for Medicinal Products for Human Use was in overall agreement with the company's development plan for OGX-011/ TV-1011 which included this Phase 3 trial.

In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize OGX-011/TV-1011. In addition to the ongoing SATURN trial assessing durable pain palliation as the primary endpoint for second-line chemotherapy in men with metastatic CRPC, the global Phase 3 clinical program also includes a Phase 3 trial in first-line chemotherapy for metastatic CRPC which assesses survival as the primary endpoint. A Phase 3 trial assessing survival as the primary endpoint in first-line treatment of advanced, unresectable non-small cell lung cancer (NSCLC) is also planned as part of the strategy to develop and commercialize OGX-011/TV-1011.

About Prostate Cancer

The National Cancer Institute reports that in 2009, approximately 192,280 new cases of prostate cancer will be diagnosed in the U.S. As the most frequently diagnosed cancer among men, one in six men will be diagnosed with prostate cancer during their lifetime. It is estimated that in 2009 in the U.S., 27,360 deaths will result due to the disease. The International Agency for Research on Cancer recently published estimates of cancer incidence and mortality in Europe in 2008. They reported 382,300 new cases of prostate cancer and 89,300 deaths related to prostate cancer.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 A ... accelerated partial breast irradiation (APBI) via interstitial brachytherapy ... with positive lymph nodes could be suitable to ... Oncology (ASTRO) guidelines place these patients in the ... at the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... SAN DIEGO and PRINCETON, N.J. ... Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic ... conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), ... the 2014 Exosomes & SingleCell Analysis Summit. ... of Exosome Sciences will give a presentation entitled: "Exosomes: ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Oncothyreon Announces Proposed Public Offerings 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... Madison, Wis. - MyWeather LLC has ... chief marketing officer. , ,Baird went to Carleton College ... former Wisconsin Governor Martin Schreiber. He has served as ... a major K-12 technology company; vice president of sales ...
... Doyle announced that the Department of Commerce's Technology ... seed capital to Wisconsin high-tech companies of fewer than ... GenTel BioSurfaces, Inc. , helping to finance their biochip ... a microscope slide that contain multiple testing factors for ...
... The old Institute of Paper Chemistry might have left ... can still feel the void. , ,Organizers of the ... filling that void Wednesday with the PTTC's grand opening in ... paper-producing state, rolling out more than 6.4 million tons of ...
Cached Biology Technology:Paper technology transfer center opens in Green Bay 2Paper technology transfer center opens in Green Bay 3
(Date:9/16/2014)... Columbia Center for Children,s Environmental Health at the Mailman ... an association between childhood asthma and prenatal exposure to ... products. Results appear online in the journal Environmental ... exposed during pregnancy to higher levels of the chemicals, ... 72 percent and 78 percent increase in risk of ...
(Date:9/16/2014)... September 13, 2014. The fire is human-caused and ... acres in size and is mostly being fueled by ... Monday night due to higher humidity. Yesterday (8/15), ... to construct a fireline on the West and North sides ... the fire: , 7 20-person Crews, 4 Hot Shot Crews, ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... 19, 2013) Columbia University College of Physicians ... announced that the Mortimer D. Sackler, M.D. Prize ... awarded to Carla Shatz, PhD, the Sapp Family ... Palo Alto, California. Dr. Shatz,s work has advanced ...
... Researchers at Plymouth University, UK, believe that findings from ... between the Early Jurassic era of 180 million years ... Through geology and palaeontology, they,ve shown how higher ... marine communities, and that while the Jurassic seas eventually ...
... elementary school students are expected to attend an INSECT EXPO ... PM on Monday, February 25 at the start of the ... Society of America (ESA), which will be held February 25-28 ... This free educational event will reinforce students, science ...
Cached Biology News:Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 2Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 3Pioneer in neural development honored with the Mortimer D. Sackler, M.D. Prize 4Jurassic records warn of risk to marine life from global warming 2
GOAT ANTI PPP2R5B...
... Molecular Probes Fc OxyBURST Green reagent ... Simons of Boston University to permit measurement ... internalization and the subsequent oxidative burst directly ... assay reagent consists of bovine serum albumin ...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI RAT RT1Bu / MOUSE Ia:BIOTIN Immunogen: Rat thymocyte membrane glycoproteins...
Biology Products: